Journal article
Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments A Systematic Review and Network Meta-analysis
Francesco Zaccardi, Zin Zin Htike, David R Webb, Kamlesh Khunti, Melanie J Davies
Annals of Internal Medicine | AMER COLL PHYSICIANS | Published : 2016
DOI: 10.7326/M15-1432
Abstract
BACKGROUND: Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the treatment of type 2 diabetes. PURPOSE: To summarize evidence for the cardiometabolic efficacy and adverse effects of once-weekly GLP-1RAs in adults with type 2 diabetes. DATA SOURCES: Electronic databases (PubMed, Web of Science, Cochrane Central Register of Controlled Trials, U.S. Food and Drug Administration, European Medicines Agency, ClinicalTrials.gov) and congress abstracts from inception through 26 September 2015. STUDY SELECTION: Randomized, controlled trials (≥ 24 weeks of follow-up) studying albiglutide, dulaglutide, once-weekly exenatide, semaglutide, and taspoglutide and reporting a..
View full abstractGrants
Funding Acknowledgements
From Sanofi Aventis to the University of Leicester.